Antiepileptic medications for the treatment of epilepsy

Seminars in Neurology

Volumn 22, Issue 3, 2002, Pages 247-258

  Morrell, Martha J ^a  

^a NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Antiepileptic drug therapy; Epilepsy

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE; BICUCULLINE; CARBAMAZEPINE; CLONAZEPAM; CLORAZEPATE; DIAZEPAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FOSPHENYTOIN SODIUM; GABAPENTIN; GABATRIL; LAMOTRIGINE; LORAZEPAM; NEW DRUG; OXCARBAZEPINE; PENTETRAZOLE; PHENOBARBITAL; PHENYTOIN; PICROTOXIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; TOPOMAX; VALPROATE SEMISODIUM; VALPROIC ACID; ZONISAMIDE;

ACNE; ALOPECIA; ANOREXIA; APLASTIC ANEMIA; ATAXIA; BEHAVIOR DISORDER; BLOOD TOXICITY; BONE MARROW TOXICITY; BRAIN CORTEX LESION; CLINICAL TRIAL; COARSE FACE; COGNITIVE DEFECT; COLLAGEN DISEASE; CONVULSION; DEPRESSION; DIPLOPIA; DROWSINESS; DRUG INDICATION; DRUG MECHANISM; DRUG MONITORING; DRUG SCREENING; DYSARTHRIA; ELECTRIC SHOCK; EPILEPSY; FATIGUE; FOCAL EPILEPSY; GASTROINTESTINAL SYMPTOM; GENERALIZED EPILEPSY; GINGIVA HYPERTROPHY; HEALTH CARE; HIRSUTISM; HUMAN; HYPERACTIVITY; INSOMNIA; IRRITABILITY; KINDLING; LIVER NECROSIS; LIVER TOXICITY; LONG TERM CARE; MENSTRUAL IRREGULARITY; MOTOR DYSFUNCTION; NAUSEA; NONHUMAN; NYSTAGMUS; PATIENT CARE; PHOTOPHOBIA; PRIORITY JOURNAL; REVIEW; SEIZURE; SENSORY STIMULATION; SIDE EFFECT; TREATMENT PLANNING; TREMOR; VERTIGO; VOMITING; WEIGHT GAIN;

ANTICONVULSANTS; DRUG INTERACTIONS; DRUG MONITORING; EPILEPSY; HUMANS; PRACTICE GUIDELINES;

EID: 0036765933     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-36645     Document Type: Review

References (43)

1. White HS, Woodhead JH, Wilcox KS, Stables JP, Kupferberg HJ, Wolf HH. Discovery and preclinical development of antiepileptic drugs. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic Drugs. 5th Ed. Philadelphia: Lippincott Williams & Wilkins; 2001:36-48
2. French JA, Dichter MA. New antiepileptic drug development: Medical perspective. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic Drugs. 5th Ed. Philadelphia: Lippincott Williams & Wilkins; 2001:49-57
3. Cramer JA, Fisher R, Menachem EB, et al. New antiepileptic drugs: Comparison of key clinical trials. Epilepsia 1999;40:590-600
4. Cereghino JJ, Mitchell WG, Murphy J, et al. Treating repetitive seizures with a rectal diazepam formulation. Neurology 1998;51:1274-1282
5. French J, Smith M, Faught E, Brown L. Practice advisory: The use of felbamate in the treatment of patients with intractable epilepsy. Neurology 1999;52:1540-1545
6. U.S. Gabapentin Study Group No. 5. Gabapentin as add-on therapy in refractory partial epilepsy: A double-blind, placebo-controlled, parallel-group study. Neurology 1993;43:2292-2298
7. Chadwick DW, Anhut H, Greiner MJ, et al. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. Neurology 1998;51:1282-1288
8. Matsuo F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology 1993;43:2284-2291
9. Dren AT, Moore EL, and the U.S. Lamictal Protocol 0.5 Clinical Trial Group. Placebo-controlled, dose response evaluation of the efficacy and safety of lamotrigine as add-on therapy in epileptic outpatients with partial seizures. Epilepsia 1993;32(suppl 3):20
10. Loiseau P, Yuen AWC, Douche B, Menageer T, Arne-Bes MC. A randomized double-blind placebo-controlled cross-over add-on trial of LAMICTAL in patients with treatment-resistant partial seizures. Epilepsy Res 1990;7:136-145
11. Ramaratnam S, Marson AG, Baker GA. Lamotrigine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2000;(3):CD001909
12. Frank LM, Enlow T, Holmes GL, et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia 1999;40:357-359
13. Steiner TJ, Dellaportas CI, Findley LJ, et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: A double-blind comparison with phenytoin. Epilepsia 1999;40:601-607
14. Motte J, Trevathan E, Arvidsson JF, Barrera MN, Mullens EL, Manasco P. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J Med 1998;339:851-852
15. Guberman AH, Besag F, Brodie M, et al. Lamotrigine-associated rash: Risk/benefit considerations in adults and children. Epilepsia 1999;40:985-991
16. Loscher W, Honack D, Rundfeldt C. Antiepileptogenic effects of the novel AED levetiracetam (ucbL059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther 1998;284:474-479
17. Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for partial seizures: Results of a double-blind, randomized clinical trial. Neurology 2000;55:236-242
18. Shorvon SD, Lowenthal A, Janz D, Bielen E, Loiseau P. Multicenter double-blind randomized, placebo controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 2000;41:1179-1186
19. Patsalos PN. Pharmacokinetic profile of levetiracetam: Toward ideal characteristics. Pharmacol Ther 2000;85:77-85
20. Barcs G, Walker EB, Elger CE, et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 2000;41:1597-1607
21. Glauser TA, Nigro M, Sachdeo R, et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology 2000;54:2237-2244
22. Schachter SC, Vazquez B, Fisher RS, et al. Oxcarbazepine: Double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology 1999;52:732-737
23. Richens A, Chadwick DW, Duncan JS, et al. Adjunctive treatment of partial seizures with tiagabine: A placebo-controlled trial. Epilepsy Res 1995;21:37-42
24. Sachdeo RC, Leroy RF, Krauss GL, et al. Tiagabine therapy for complex partial seizures: A dose-frequency study. Arch Neurol 1997;54:595-601
25. Uthman BM, Rowan AJ, Ahmann PA, et al. Tiagabine for complex partial seizures: A randomized, add-on, dose-response trial. Arch Neurol 1998;55:56-62
26. Biton V, Montouris GD, Ritter F, et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Neurology 1999;52:1330-1337
27. Abou-Khalil B. Topiramate in the long-term management of refractory epilepsy. Topiramate YOL Study Group. Epilepsia 2000;41(suppl 1):S72-S76
28. Ritter F, Glauser TA, Elterman RD, Wyllie E. Effectiveness, tolerability, and safety of topiramate in children with partial-onset seizures. Epilepsia 2000;41(suppl 1):S82-S85
29. Jette NJ, Marson AG, Kadir ZA, Hutton JL. Topiramate for drug resistant epilepsy. Cochrane Database Syst Rev 2000;(2):CD001417
30. Glauser TA, Levisohn PM, Ritter F, Sachdeo RC. Topiramate in Lennox-Gastaut syndrome: Open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group. Epilepsia. 2000;41(suppl 1):S86-S90
31. Chadwick DW, Marson AG. Zonisamide for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2000;(2):CD001416
32. Oommen KJ, Mathews S. Zonisamide: A new antiepileptic drug. Clin Neuropharmacol 1999;22:192-200
33. Semah F, Picot MC, Adam C, et al. Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 1998;51:1256-1262
34. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: A guideline for discontinuing antiepileptic drugs in seizure-free patients (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1996;47:600-602
35. Medical Research Council Antiepileptic Drug Withdrawal Study Group. Randomised study of antiepileptic drug withdrawal in patients in remission. Lancet 1991;337:1175-1180
36. Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia 2001;42:1255-1260
37. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-319
38. Dlugos DJ, Sammel MD, Strom BL, Farrar JT. Response to first drug trial predicts outcome in childhood temporal lobe epilepsy. Neurology 2001;57:2259-2264
39. Karceski S, Morrell M, Carpenter D. The Expert Consensus Guideline Series: The treatment of epilepsy. Epilepsy Beh 2001;2:A1-A50
40. Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of AED drugs. N Engl J Med 2001;344:1132-1138
41. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: Management issues for women with epilepsy (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1998;51:944-948
42. Zahn CA, Morrell MJ, Collins SD, Labiner DM, Yerby MS. Management issues for women with epilepsy: A review of the literature. American Academy of Neurology Practice Guidelines. Neurology 1998;51:949-956
43. Yerby MS, Annegers JF, Bruni J, et al. A North American registry for epilepsy and pregnancy: A unique public/private partnership pf health surveillance. Epilepsia 1998;39:793-798